Nirsevimab reduced respiratory syncytial virus infections and hospitalisations in preterm infants in Phase IIb trial
Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose Results published in the New England Journal of MedicineNirsevimab showed a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine . The trial demonstrated for the first time that a